---
layout: report
type: daily
topic_slug: type_2_diabetes
topic_display: "Type 2 diabetes"
date: 2025-10-08
run_id: type_2_diabetes_20251008_060838
theme: "Advanced Medications for Type 2 Diabetes: GLP-1s and SGLT2s"
persona: "Persona.INFORMED_PATIENT"
source_plan_path: "/home/runner/work/health_buddy_app/health_buddy_app/.results/type_2_diabetes/weekly_plan/2025-10-06/plan.json"
permalink: /topics/type_2_diabetes/daily/2025-10-08/type_2_diabetes_20251008_060838/
title: "Type 2 diabetes — 2025-10-08"
---

# Advanced Medications for Type 2 Diabetes: GLP-1s and SGLT2s – A Patient's Essential Guide

Managing Type 2 diabetes has advanced significantly. Two powerful medication classes, GLP-1 Receptor Agonists (GLP-1s) and Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, offer benefits beyond blood sugar control, impacting heart and kidney health.

## GLP-1 Receptor Agonists: Dual Benefits

GLP-1s (e.g., semaglutide [Ozempic, Rybelsus, Wegovy], liraglutide [Victoza, Saxenda], dulaglutide [Trulicity]) mimic a natural gut hormone, stimulating insulin, slowing stomach emptying, and reducing liver glucose production.
*   **Indications:** Ozempic and Rybelsus are for Type 2 diabetes and reducing cardiovascular risk. Wegovy and Saxenda are primarily for chronic weight management (with or without diabetes).
*   **Contraindications:** Not for Type 1 diabetes, or if you have a personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
*   **Side Effects:** Common: nausea, vomiting, diarrhea. Manage by starting with low doses and eating smaller meals. Rare but serious: pancreatitis, gallbladder problems.
*   **Administration:** Often weekly injections; oral Rybelsus is a daily pill. Store as directed.

## SGLT2 Inhibitors: Heart and Kidney Protectors

SGLT2 inhibitors (e.g., empagliflozin [Jardiance], dapagliflozin [Farxiga], canagliflozin [Invokana]) work by causing kidneys to excrete excess sugar in urine, lowering blood sugar.
*   **Indications:** Beyond Type 2 diabetes, empagliflozin and dapagliflozin are approved for heart failure and chronic kidney disease, even in non-diabetic individuals.
*   **Contraindications:** Not for severe kidney impairment or dialysis.
*   **Side Effects:** Common: genitourinary infections (e.g., yeast infections, UTIs) due to glucose in urine. Prevention: good hygiene. Seek medical attention for persistent symptoms. Rare but serious: diabetic ketoacidosis (DKA), including euglycemic DKA (normal blood sugar), dehydration/hypotension. Historically, canagliflozin had a warning for amputation risk, but current evidence suggests this is rare and often linked to pre-existing risk factors.
*   **Administration:** Typically a daily pill.

## Important Practical Guidance

*   **Monitoring:** Regularly check blood sugar, A1C, weight, blood pressure, and kidney function (eGFR, albumin-to-creatinine ratio) with your doctor.
*   **Questions for your Doctor:**
    *   "Based on my health, which specific medication in these classes is best for me?"
    *   "What are the most important side effects I should watch for, and when should I contact you?"
    *   "How will we monitor the effectiveness and safety of this medication?"
*   **Cost & Insurance:** These medications can be expensive. Discuss cost and insurance coverage with your doctor and pharmacist.

These advanced medications offer vital protection for your heart and kidneys, enhancing long-term health and quality of life. Discuss your personal health profile thoroughly with your doctor.
